Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
It is advocated that prolonged infusion of beta-lactamic antibiotics provides better bactericidal effect. The aim of the present study is to randomize patients a to extended cefepime infusion regimen (lasting four hours) or to a usual infusion regimen (not lasting more than thirty minutes) and evaluate the clinical efficacy of this theoretical pharmacokinetic advantage.
Introduction: it has been proved that the main determinant for microbiological cure gram-negative infections treated with cefepime is the time above minimal inhibitory concentration (T>MIC). Although this particular pharmacokinetic property have never been proved in clinical trials utilizing cefepime, intervention studies with other betalactamic antibiotics, such as pipercillin-tazobactam, showed clinical benefit.
Objective: to evaluate if prolonged infusion (lasting 4 hours) with cefepime translate into better clinical outcomes.
Methods: the investigators aim to conduct an open-label, unique-centered, randomized controlled trial using cefepime in prolonged infusions in patients being treated for urinary or respiratory tract infections. Patients developing these infections after 72 hours of hospital admission, requiring the use of broader spectrum antibiotics after clinical failure or isolating gram-negative bacteria from adequate sample sensible to cefepime will be enrolled. The use of a second antibiotic such as clindamycin, vancomycin or metronidazole will be allowed.
Interventions: the investigators aim to randomize 134 patients to two different treatment arms, the intervention arm who will receive the medication in a four hour lasting infusion, and the active control arm who will receive the medication in a 30 minutes lasting infusion. The randomization will be conducted in blocks of ten patients each, and it will be balance according to the patients age (older or younger than 65 years old) and presence of SIRS criteria.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Prolonged Cefepime Infusion | Experimental | Cefepime infusions should last 4 hours at least |
|
| Usual Cefepime Infusion | Active Comparator | Cefepime infusion should last no more than 30 minutes |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prolonged Cefepime Infusion | Drug | Cefepime infusion should last at least 4 hours with the aide of an infusion bomb |
|
| Measure | Description | Time Frame |
|---|---|---|
| Death | Death in 30 days since randomization | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Death | Death in 14 days since randomization | 14 days |
| Duration of hospital stay | Duration of hospital stay | 30 days since randomization |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| André Dias Américo | Contact | +555193112207 | adamerico@hcpa.edu.br |
| Name | Affiliation | Role |
|---|---|---|
| Eduardo Sprinz | Hospita de Clínicas de Porto Alegre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital de Clínicas de Porto Alegre | Recruiting | Porto Alegre | Rio Grande do Sul | Brazil |
Not provided
| ID | Term |
|---|---|
| D014552 | Urinary Tract Infections |
| D012141 | Respiratory Tract Infections |
| ID | Term |
|---|---|
| D007239 | Infections |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Usual Cefepime Infusion | Drug | Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes |
|
|
| Intensive care unit (ICU) admission | Intensive care necessity for any reason | 30 days since randomization |
| Duration of intensive care unit (ICU) stay | Number of days when intensive care was considered necessary | 30 days since randomization |
| Treatment change | Treatment change required based com clinical or microbiological data | 3 days after randomization |
| Treatment success | Patient reaching the completion until it end with infection resolution | 30 days since randomization |
| Time to clinical stability | Time required for patient to reach the normalization of all following vital signs: that is, body temperature lower than 37,9 degrees celsius, a cardiac rate lower than 100 beats per minute and a respiratory rate lower than 25 respiratory movements per minute and peripheral oxygen saturation higher than 91% with low oxygen requirement (that is 4 liters per minute delivered by nasal canula) | 3 days |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D012140 | Respiratory Tract Diseases |